Korro Bio, Inc.KRROEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Korro Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative RNA editing therapies for rare and severe genetic diseases. It leverages its proprietary oligonucleotide platform to target disease-causing mutations, with core pipelines covering ophthalmology, respiratory and neuromuscular disorder segments, striving to address unmet medical needs for global patients.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| New Enterprise Associates 17, L.P. | 11.80% | 1.1M | ▼ -1.60pp | 2024-04-24 |
| Deep Track Capital, LP | 9.14% | 850.0K | ▲ +1.44pp | 2024-11-14 |
| Platanus Investment LLC | 6.80% | 540.2K | — | 2023-11-17 |
| Citadel Advisors LLC | 6.60% | 8.0M | ▼ -0.20pp | 2024-02-14 |
| FMR LLC | 6.23% | 579.6K | ▼ -2.86pp | 2024-11-12 |
| David L. Lucchino | 6.20% | 2.4M | — | 2023-10-12 |
| Point72 Asset Management, L.P. | 4.80% | 444.9K | ▲ +1.50pp | 2024-11-14 |
| Invus Public Equities, L.P. | 4.50% | 413.1K | ▼ -0.70pp | 2024-07-12 |
| Eventide Asset Management, LLC | 4.21% | 391.2K | ▼ -2.62pp | 2024-11-14 |
| Cormorant Global Healthcare Master Fund, LP | 3.90% | 312.1K | ▼ -1.87pp | 2024-02-14 |
| Cormorant Asset Management, LP | 2.86% | 265.8K | — | 2024-11-14 |
Insider Transactions
Net 90d: +$20.71M · buys $20.71M / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-31 | Lynx1 Capital Management LP | 10% Owner | Buy (open market) | 520 | $10.60 | $5.5K |
| 2026-03-10 | L.P. New Enterprise Associates 17 | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | Carmen Chang | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | SANDELL SCOTT D | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | Rick Yang | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | Ali Behbahani | Director | Grant | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | BASKETT FOREST | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | Mathers Edward T | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | Mohamad Makhzoumi | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
| 2026-03-10 | Walker Paul Edward | 10% Owner | Buy (open market) | 207.1K | $11.11 | $2.30M |
1–10 of 11
Page 1 / 2